Pluristem Initiates Final Validation of New Manufacturing Facility

Pluristem Initiates Final Validation of New Manufacturing Facility

Capacity Design of Over 150,000 PLX Doses Annually

HAIFA, Israel, Dec. 27, 2012 (GLOBE NEWSWIRE) -- Pluristem Therapeutics, Inc.
(Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell
therapies, announced today it has initiated the final validation steps for its
new "state-of-the-art" manufacturing facility prior to taking possession of
the facility. These steps include the validation of several installation
systems including as heating, ventilation and air conditioning (HVAC), water,
oil free air and sterile room systems.

Zami Aberman, Chairman and CEO of Pluristem commented, "I am extremely proud
of our team in meeting milestones for the completion of the world's first
commercial cell therapy manufacturing facility. Assuming the PLX cells product
candidates are successfully developed and approved by the regulators, we
believe that the new facility would have the capacity to produce PLX cells for
the treatment of over 150,000 patients annually estimated by Pluristem at $1
billion in production value. Additionally, as clinical trials are approved by
regulators for additional indications, our new facility will enable us to
supply PLX cells to conduct these trials in parallel."

About Pluristem Therapeutics

Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR) is a leading developer
of placenta-based cell therapies. The Company's patented PLX (PLacental
eXpanded) cells are a drug delivery platform that releases a cocktail of
therapeutic proteins in response to a host of local and systemic inflammatory
and ischemic diseases. PLX cells are grown using the company's proprietary 3D
micro-environmental technology and are an "off-the-shelf" product that
requires no tissue matching prior to administration. Pluristem is focusing on
the development of PLX cells administered locally to potentially treat
systemic diseases and potentially obviating the need to use the intravenous
route.

Pluristem has a strong patent and patent applications portfolio, company-owned
GMP certified manufacturing and research facilities, strategic relationships
with major research institutions and a seasoned management team. For more
information visit www.pluristem.com, the content of which is not part of this
press release.

The Pluristem Therapeutics Inc. logo is available a
http://www.globenewswire.com/newsroom/prs/?pkgid=6882

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of
the "safe harbor" provisions of the Private Securities Litigation Reform Act
of 1995 and federal securities laws. For example, when we discuss our new
manufacturing facility, its validation process, its planned capacity for
production of PLX cells and estimated production value assuming the PLX cells
product candidates are successfully developed and approved by the regulators,
or when we say that as clinical trials are approved by regulators for
additional indications, our new facility will enable us to supply PLX cells to
conduct these trials in parallel, we are using forward-looking statements.
These forward-looking statements are based on the current expectations of the
management of Pluristem only, and are subject to a number of factors and
uncertainties that could cause actual results to differ materially from those
described in the forward-looking statements. The following factors, among
others, could cause actual results to differ materially from those described
in the forward-looking statements: changes in technology and market
requirements; we may encounter delays or obstacles in launching and/or
successfully completing our clinical trials; our products may not be approved
by regulatory agencies, our technology may not be validated as we progress
further and our methods may not be accepted by the scientific community; we
may be unable to retain or attract key employees whose knowledge is essential
to the development of our products; unforeseen scientific difficulties may
develop with our process; our products may wind up being more expensive than
we anticipate; results in the laboratory may not translate to equally good
results in real surgical settings; results of preclinical studies may not
correlate with the results of human clinical trials; our patents may not be
sufficient; our products may harm recipients; changes in legislation;
inability to timely develop and introduce new technologies, products and
applications; loss of market share and pressure on pricing resulting from
competition, which could cause the actual results or performance of Pluristem
to differ materially from those contemplated in such forward-looking
statements. Except as otherwise required by law, Pluristem undertakes no
obligation to publicly release any revisions to these forward-looking
statements to reflect events or circumstances after the date hereof or to
reflect the occurrence of unanticipated events. For a more detailed
description of the risks and uncertainties affecting Pluristem, reference is
made to Pluristem's reports filed from time to time with the Securities and
Exchange Commission.

CONTACT: Pluristem Therapeutics Inc.:

         William Prather R.Ph., M.D. Sr. VP Corporate Development
         1-303-883-4954
         William.PratherMD@pluristem.com

         Daya Lettvin
         Investor & Media Relations Director
         +972-54-674-5580
         daya@pluristem.com

Pluristem Therapeutics Inc. Logo
 
Press spacebar to pause and continue. Press esc to stop.